Research article summary (published 29 Nov 2005):

High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer.

Full Abstract

PURPOSE: Thioredoxin overexpression is suggested to be associated with resistance to several chemotherapeutic agents in vitro. In the present study, it has been studied whether or not high thioredoxin expression is associated with resistance to docetaxel therapy in breast cancer patients. Patients and Methods: Sixty-three primary breast cancer patients were treated with docetaxel (60 mg/m(2), q3w) for four cycles in the neoadjuvant setting. Expression of thioredoxin, estrogen receptor (ER), p53, BRCA-1, and Bcl-2 in tumor tissues obtained before docetaxel therapy was studied by immunohistochemistry (thioredoxin, p53, BRCA-1, and Bcl-2) and enzyme immunoassay (ER), and relationship of expression of these biomarkers with a pathologic response was investigated.RESULTS: There was no significant correlation between the expression of p53, BRCA-1, or Bcl-2 and a response to docetaxel. However, tumors with high thioredoxin expression showed a significantly lower response rate (0%) than those with low thioredoxin expression (30.6%; P = 0.018) and ER-negative tumors showed a significantly higher response rate (32.4%) than ER-positive tumors (10.7%; P = 0.043). Thioredoxin expression significantly increased after docetaxel therapy (mean, 56.1%) as compared with that before docetaxel therapy (mean, 28.6%; P < 0.0001) but there was no significant association between the extent of increase in thioredoxin expression and response.CONCLUSION: High thioredoxin expression in prechemotherapy tumor samples, but not the increase in thioredoxin expression induced by docetaxel, is associated with resistance to docetaxel in breast cancer. Thioredoxin and ER might be clinically useful in the prediction of a response to docetaxel.

Author information

Author/s: Kim, Seung Jin (SJ); Miyoshi, Yasuo (Y); Taguchi, Tetsuya (T); Tamaki, Yasuhiro (Y); Nakamura, Hajime (H); Yodoi, Junji (J); Kato, Kikuya (K); Noguchi, Shinzaburo (S);

Affiliation: Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Suita City, Osaka, Japan.

Journal and publication information

Publication Type: Journal Article

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res), published in United States. (Language: eng)

Reference: 2005-Dec; vol 11 (issue 23) : pp 8425-30

Dates: Created 2005/12/02; Completed 2006/01/24; Revised 2009/11/03;

PMID: 16322305, status: MEDLINE (last retrieved date: 11/3/2009)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MeSH Headings (categories) shown below.

Antineoplastic Agents, Phytogenic - therapeutic use BRCA1 Protein - metabolism Breast Neoplasms - drug therapy; metabolism; pathology Carcinoma, Ductal, Breast - drug therapy; metabolism; pathology Chemotherapy, Adjuvant Drug Resistance, Neoplasm Female Humans Middle Aged

Middle Aged Neoadjuvant Therapy Neoplasm Invasiveness - pathology Neoplasm Staging Proto-Oncogene Proteins c-bcl-2 - metabolism Receptors, Estrogen - metabolism Taxoids - therapeutic use Thioredoxins - metabolism Tumor Suppressor Protein p53 - metabolism

Note: Bold headings indicate primary MeSH headings or qualifiers.

Associated Chemicals: Antineoplastic Agents, Phytogenic (0) ; BRCA1 Protein (0) ; Proto-Oncogene Proteins c-bcl-2 (0) ; Receptors, Estrogen (0) ; Taxoids (0) ; Tumor Suppressor Protein p53 (0) ; docetaxel (114977-28-5) ; Thioredoxins (52500-60-4)

Related articles

These are the most related articles currently in our database:

• Potential predictive factors for response to weekly paclitaxel treatment in patients with metastatic breast cancer. 30 Jan 2005
• Current status of taxanes as adjuvant therapy for early-stage breast cancer. 30 Aug 2005
• Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study. 24 Mar 2008
• Paclitaxel-induced remission in docetaxel-refractory anthracycline-pretreated metastatic breast cancer. 30 Jul 2000
• [Taxanes in the adjuvant and neoadjuvant therapy of breast cancer] 30 Dec 2003
• Successful treatment of malignant pericardial effusion, using weekly paclitaxel, in a patient with breast cancer. 29 Sep 2006
• Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers. 3 Jul 2006
• Taxanes in the treatment of early breast cancer. 31 Oct 2005
• NICE approves docetaxel for early breast cancer. 5 Oct 2006
• A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel. 28 Feb 2004

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a larger map of 100+ related articles.